A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Inflammatory Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: DRUG: Eribulin|DRUG: Adriamycin|DRUG: Cyclophosphamide
Sponsor: Dana-Farber Cancer Institute
Collaborators: Eisai Inc.